Status:
TERMINATED
SCRI Tissue Testing Registry
Lead Sponsor:
SCRI Development Innovations, LLC
Conditions:
Melanoma
Myelodysplastic Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written ...
Detailed Description
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written ...
Eligibility Criteria
Inclusion
- Patients must be \>= 18 years of age.
- Patients must be able to provide written informed consent.
Exclusion
- Not Applicable
Key Trial Info
Start Date :
May 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00965861
Start Date
May 1 2010
End Date
February 1 2013
Last Update
August 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023